Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria in the gut lumen are a diverse group of microbial species that reside or invade the gastrointestinal tract and contribute to disease through mechanisms such as infection, toxin production, disruption of mucosal barriers, and induction of host inflammatory responses. They are distinct from commensal, beneficial gut bacteria, and their overgrowth or increased virulence often correlates with dysbiosis—an imbalance in the microbial community. Targeting these bacteria is central to the management of a wide variety of gut-related infectious and inflammatory diseases.
Direct antimicrobial action (cell wall synthesis inhibition, protein synthesis inhibition, DNA replication inhibition, etc.) Suppression of virulence factor expression Restoration of normal microbiota (competition/exclusion)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium in gut lumen.